큐 바이오파마(CUE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $34.20 (+10.04%), 시가총액 $0.08B, 52주 범위 $0.18 ~ $35.73.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as
큐 바이오파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
큐 바이오파마의 현재 주가는 $34.20 (+10.04%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
큐 바이오파마의 시가총액은 약 $0.08B입니다.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United S